Trials / Terminated
TerminatedNCT03285308
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 336 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo injected subcutaneously twice daily. |
| DRUG | Relamorelin | Relamorelin 10 micrograms (μg) injected subcutaneously twice daily. |
Timeline
- Start date
- 2017-09-29
- Primary completion
- 2020-07-08
- Completion
- 2020-07-08
- First posted
- 2017-09-18
- Last updated
- 2021-07-29
- Results posted
- 2021-07-29
Locations
216 sites across 14 countries: United States, Australia, Bulgaria, France, India, Israel, Malaysia, Philippines, Poland, Singapore, South Korea, Spain, Thailand, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03285308. Inclusion in this directory is not an endorsement.